RGDS

RGDS (Arg-Gly-Asp-Ser) is the prototype integrin-binding tetrapeptide sequence derived from fibronectin. It is the minimal consensus motif recognized by multiple integrin receptors and serves as the foundational tool peptide in cell adhesion, biomaterials surface functionalization, and integrin pharmacology research.

RGDS competes with extracellular matrix proteins (fibronectin, vitronectin, fibrinogen) for binding to integrin receptors — particularly αvβ3, αvβ5, α5β1, and αIIbβ3. The Asp residue forms a key salt bridge with the integrin metal ion-dependent adhesion site (MIDAS), while Arg contributes electrostatic interactions. In solution, RGDS acts as a competitive antagonist of cell-matrix adhesion. When tethered to biomaterial surfaces, it promotes controlled cell attachment. The Ser residue at the C-terminus confers selectivity for certain integrin subtypes compared to RGD alone.

RGDS has been foundational to integrin biology since Pierschbacher and Ruoslahti defined the RGD sequence in fibronectin in 1984. It is widely used to functionalize hydrogels, scaffolds, and nanoparticles for tissue engineering. Soluble RGDS has been studied as an antiplatelet agent (αIIbβ3 antagonist). Countless biomaterial studies use RGDS density to tune cell adhesion, spreading, and fate. No clinical drug development has advanced RGDS itself, but structural analogs (eptifibatide, tirofiban) are FDA-approved antithrombotics based on RGD pharmacophore.